Evogene (EVGN) Earnings Dates, Call Summary & Reports

Compare

641 Followers

Earnings Data

Report Date

May 27, 2026

TBA (Confirmed)

Period Ending

2026 (Q1)

Consensus EPS Forecast

-0.27

Last Year’s EPS

-0.38

Same Quarter Last Year

Analyst Consensus

Moderate Buy

Based on 1 Analysts Ratings

Earnings Call Summary

Q4 2025

Earnings Call Date:Mar 05, 2026|

% Change Since:

Earnings Call Sentiment|Neutral

The call presents a balanced mix of positive strategic and operational developments and significant near-term financial and operational challenges. Positives include a clear strategic refocus on ChemPass AI, strong technical milestones (38 billion-molecule foundation model, 90% design precision), new automation collaboration with Google Cloud, key partnerships (Bayer, Corteva) and material reductions in operating costs that improved annual operating and net losses substantially. Negatives include meaningful revenue declines (≈30% year-over-year and ≈80% in Q4), a large inventory impairment (~$2.2M) that drove higher cost of revenues, a sharp reduction in financing income (~85% year-over-year), a deteriorating Q4 operating/net loss profile, and modest cash balances reliant in part on one-time discontinued-operations proceeds and future collaboration or financing catalysts. Overall, the strategic and technical progress is offset by current top-line weakness and one-time impairment impacts, leading to a balanced view of prospects and risks.

Company Guidance

The company guided that its lower cost structure will be sustained, citing operating expenses net of approximately $13.8M for 2025 (down from ~$22M in 2024) and fourth‑quarter operating expenses of ~$3.2M (vs. ~$4.3M in Q4 2024); consolidated cash, cash equivalents and short‑term deposits were about $13M as of 12/31/2025 with consolidated cash usage of ~ $3M in Q4 2025 (and ~$2.4M excluding Lavie Bio and Biomica), and management said cash after expected Lavie Bio/Biomica distributions should cover needs to at least mid‑next year (or “a little more than 1.5 years” without additional transactions); Feb 2026 warrant inducement brought gross proceeds of ~ $3.4M and issued new warrants to purchase up to 5,076,924 shares exercisable at $1.25; 2025 revenue was ~ $3.9M (down ~$1.7M from $5.6M), Q4 revenue ~$0.3M (vs. $1.5M), cost of revenues ~$4.1M (including a ~$2.2M Casterra inventory impairment), Q4 cost of revenues $2.3M, R&D net ~$8M (vs. $12.5M), S&M ~$1.5M (vs. $2M), G&A ~$4.3M (vs. $7M), operating loss ~$14M (vs. $18.8M) and 2025 net loss ~$7.8M (vs. $18.1M), while discontinued‑operations produced income of ~$5.7M (including a ~$6.4M gain on sale); on the technology side they cited ChemPass AI trained on a 38‑billion‑molecule universe and delivering ~90% design precision, positioning expected near‑term catalysts from further tech and pharma/ag collaborations.

Strategic Refocus on ChemPass AI and High-Impact Markets

Company completed a strategic transformation to concentrate on a single computational engine, ChemPass AI, and two markets (human health small-molecule drugs and agriculture ag-chemicals), streamlining organization, divesting noncore assets and aligning business development to the refined strategy.

Platform Scale and Technical Milestones

ChemPass AI foundation model built on a 38 billion molecule universe, enabling access to diverse chemical space and multi-parameter optimization from day 1; first Google Cloud collaboration completed in mid-2025 and delivered 90% design precision (a 3x improvement on benchmarks).

New Automation Collaboration with Google Cloud

Second collaboration with Google Cloud initiated in Feb 2026 to integrate Vertex AI agents for automating workflows and reducing manual errors — a move toward autonomous discovery and scalability for pharma and agriculture partnerships.

Partnerships and Early Commercial Engagements

Multiple collaborations established: four publicly disclosed human health collaborations, and strategic agriculture collaborations with Bayer and Corteva; advancing partnered drug discovery programs and expecting scaled activity across 2026.

Substantial Operating Expense Reductions

Total operating expenses (net) fell to approximately $13.8M in 2025 from ~$22.0M in 2024 — a decrease of ~$8.2M (≈37%); Q4 operating expenses decreased to ~$3.2M from ~$4.3M (≈25% decline). Company expects reduced expense level to be sustained.

Decline in R&D, Sales & Admin Costs

R&D expenses net fell to ~$8.0M from $12.5M (down ~$4.5M, ≈36%); Sales & Marketing decreased to ~$1.5M from $2.0M (≈25%); General & Administrative decreased to ~$4.3M from $7.0M (≈39%).

Improved Annual Operating and Net Loss

Operating loss improved to ~ $14.0M in 2025 from ~$18.8M in 2024 (improvement of ~$4.8M, ≈25%); net loss improved to ~ $7.8M from ~$18.1M (improvement of ~$10.3M, ≈57%), driven by lower operating expenses and income from discontinued operations (gain on sale).

Cash Position and Near-Term Financing

Consolidated cash, cash equivalents and short-term deposits of ~ $13.0M as of Dec 31, 2025; Q4 cash usage ~ $3.0M (or ~$2.4M excluding Lavie Bio and Biomica). Feb 2026 warrant inducement generated gross proceeds of ~ $3.4M, and expected distributions from Lavie Bio and Biomica may extend runway to ~1.5 years or more.

Evogene (EVGN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

EVGN Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
May 27, 2026	2026 (Q1)	-0.27 / -	-0.38	―	―	―
Mar 05, 2026	2025 (Q4)	-0.26 / -0.61	0.06	-1115.00% (-0.67)	―
Nov 20, 2025	2025 (Q3)	-0.41 / 0.44	-1.31	133.89% (+1.75)	―
Aug 19, 2025	2025 (Q2)	-0.63 / -0.50	-1.06	52.83% (+0.56)	―
May 21, 2025	2025 (Q1)	-0.51 / -0.38	-0.8	52.50% (+0.42)	―
Mar 06, 2025	2024 (Q4)	-0.72 / 0.06	-1.3	104.62% (+1.36)
Nov 21, 2024	2024 (Q3)	-1.01 / -1.31	-0.8	-63.75% (-0.51)	―
Aug 22, 2024	2024 (Q2)	-1.25 / -1.06	-1.7	37.65% (+0.64)	―
May 23, 2024	2024 (Q1)	-0.95 / -0.80	-1.5	46.67% (+0.70)	―
Mar 07, 2024	2023 (Q4)	-1.40 / -1.30	-0.7	-85.71% (-0.60)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

EVGN Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Mar 05, 2026	$0.84	$0.79	-6.21%
Nov 20, 2025	$1.17	$1.08	-7.69%
Aug 19, 2025	$1.33	$1.27	-4.51%
May 21, 2025	$1.27	$1.18	-7.09%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Evogene (EVGN) report earnings?

Evogene (EVGN) is schdueled to report earning on May 27, 2026, TBA (Confirmed).

What is Evogene (EVGN) earnings time?

Evogene (EVGN) earnings time is at May 27, 2026, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is EVGN EPS forecast?

EVGN EPS forecast for the fiscal quarter 2026 (Q1) is -0.27.